REDUCTION IN LIPOPROTEIN (A) WITH EVOLOCUMAB: ELUCIDATION OF THE ROLE OF THE LDL RECEPTOR FROM CLINICAL TRIALS AND IN-VITRO MODELS

Lp(a) is an independent risk factor for cardiovascular disease risk. Statins increase low-density lipoprotein receptor (LDLR) activity but have little effect on Lp(a), while the PCSK9-inhibitor evolocumab consistently reduces Lp(a) 20-30% by a yet unknown mechanism. We investigated the possible role